...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Carbon-ion re-irradiation for recurrences after initial treatment of stage I non-small cell lung cancer with carbon-ion radiotherapy
【24h】

Carbon-ion re-irradiation for recurrences after initial treatment of stage I non-small cell lung cancer with carbon-ion radiotherapy

机译：碳离子再辐射在初始治疗I期非小细胞肺癌后复发，碳离子放射疗法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Purpose To investigate carbon-ion radiotherapy (CIRT) for in-field recurrence of stage I non-small cell lung cancer (NSCLC) initially treated with CIRT. Materials and methods From January 2007 to March 2014, patients initially treated for stage I NSCLC with CIRT and relapsed in-field were candidates. Overall survival (OS) rate, local control (LC) rate, progressive free survival (PFS) rate, dose to the lungs and skin, and adverse effects were analyzed. Results Twenty-nine patients were eligible. Median age at re-irradiation was 74years (range 53–90). Median observation period from the first day of re-irradiation was 29months (4–88months). Median prescribed dose was 46.0Gy (RBE) as initial treatment and 66.0Gy (RBE) in 12 fractions as re-irradiation. Two-year OS, LC, and PFS rates after re-irradiation were 69.0% (95% CI: 50.3–83.0), 66.9% (95% CI: 47.5–81.9), and 51.7% (95% CI: 34.1–68.9). Median skin maximum dose was 53.8Gy (RBE) (range 4.4–103.1) and median of mean lung dose was 7.3Gy (RBE) (range 2.6–14.0). There were no severer than grade 2 adverse effects except one (3.4%) grade 3 bacterial pneumonia, which was not considered radiation-induced. Conclusion CIRT for stage I NSCLC local recurrence is an acceptable definitive re-treatment.
机译：摘要目的，研究碳离子放射治疗（岩体）的阶段I阶段阶段复发性，最初用肝脏治疗。从2007年1月到2014年3月的材料和方法，患者最初对I阶段的NSCLC进行治疗，患有肝脏并复发的候选人。分析了整体存活（OS）率，局部对照（LC）率，渐进式自由存活（PFS）率，对肺和皮肤的剂量，以及不良反应。结果29名患者有资格。重新照射中位年龄为74年（范围53-90）。再辐射第一天的中位观察期是29个月（4-88个月）。中位数的剂量为46.0gy（RBE）作为初始治疗，12分馏器中的66.0gy（RBE）作为再辐照。重新辐照后的两年型号，LC和PFS率为69.0％（95％CI：50.3-83.0），66.9％（95％CI：47.5-81.9）和51.7％（95％CI：34.1-68.9 ）。中位皮肤最大剂量为53.88.8880（RBE）（范围4.4-103.1），平均肺剂量的中位数为7.3gy（RBE）（范围2.6-14.0）。除了一个（3.4％）3级细菌肺炎外，没有严重的2级不良反应，其未被视为辐射诱导。结论阶段的瞬间INSCLC局部复发是可接受的最终再治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号